Founded in 1997 in the Cleveland area, Oakwood Labs develops and manufactures sustained-release injectable pharmaceuticals through its proprietary Chroniject™ polymer microsphere platform. Its integrated operation connects formulation research and development with an FDA-approved aseptic cGMP facility, supporting products from early feasibility through clinical supply and commercial manufacturing. Oakwood has worked on more than 100 long-acting injectable projects and currently manufactures five FDA-approved commercial products.
FDA 21 CFR Part 210 and 211 cGMP
compliance_program
FDA 21 CFR Part 4 Regulation of Combination Products
compliance_program
FDA 21 CFR Part 11 Electronic Records and Electronic Signatures
compliance_program
ICH Q10 Pharmaceutical Quality System
compliance_program
FDA-approved aseptic cGMP manufacturing facility
registration